Who
Sean P. Nolan
Director
Company insider
Files Form 4 as: Director, Ventas; Chief Executive Officer, Taysha Gene Therapies; Director, Neurogene; President & CEO, AveXis; EVP & Cbo, Intermune.
In numbers
- Trades disclosed
- 96
- Buys
- 4
- Sells
- 12
- Bought
- $431K
- Sold
- $6.4M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 7 Mar 2013
- Last trade
- 13 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 15 May 2026 | VTR VentasREITs | SEC FORM 4 Code A | $185K2,047 at $90.35 | filing |
| 13 May 2026filed 15 May 2026 | VTR VentasREITs | SEC FORM 4 Code A | $185K2,047 at $90.35 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $190K41,312 at $4.61 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $190K41,312 at $4.61 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $650K136,789 at $4.75 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $650K136,789 at $4.75 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —1,008,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —1,008,000 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | VTR VentasREITs | SEC FORM 4 Code A | $185K2,882 at $64.18 | filing |
| 2 Jan 2025filed 3 Jan 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —892,500 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —892,500 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | VTR VentasREITs | SEC FORM 4 Code A | $175K3,648 at $47.96 | filing |
| 2 Jan 2024filed 4 Jan 2024 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,184,688 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —1,184,688 at $0.00 | filing |
| 14 Dec 2023filed 18 Dec 2023 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —466,550 at $0.00 | filing |
| 16 Aug 2023filed 16 Aug 2023 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Bought | $400K444,444 at $0.90 | filing |
| 16 May 2023filed 18 May 2023 | VTR VentasREITs | SEC FORM 4 Code A | $175K3,835 at $45.63 | filing |
| 30 Dec 2022filed 4 Jan 2023 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,106,131 at $0.00 | filing |
News
Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)TSHA · dailypolitical.com · 12 Oct 2026Taysha Gene Therapies (NASDAQ:TSHA) Stock Falls 5.4% – Here's WhyTSHA · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Sean P. Nolan; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.